Intermediate Hepatobiliary Cells Predict an Increased Risk of Hepatocarcinogenesis in Patients With Hepatitis C Virus-Related Cirrhosis

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Intermediate Hepatobiliary Cells Predict an Increased Risk of Hepatocarcinogenesis in Patients With Hepatitis C Virus-Related Cirrhosis"

Transcription

1 GASTROENTEROLOGY 2010;139: Intermediate Hepatobiliary Cells Predict an Increased Risk of Hepatocarcinogenesis in Patients With Hepatitis C Virus-Related Cirrhosis MARIANNE ZIOL,* JEAN CHARLES NAULT, MOUNIR AOUT, NATHALIE BARGET,* MARYLINE TEPPER,* ANTOINE MARTIN, JEAN CLAUDE TRINCHET, NATHALIE GANNE CARRIÉ, ERIC VICAUT, MICHEL BEAUGRAND, and GISELE N KONTCHOU *Pathology Department, and Hepatology Unit, CHU Jean Verdier, Assistance Publique, Hôpitaux de Paris (AP-HP), Bondy and Paris 13 University, Bobigny, France; Clinical Research Unit Lariboisière/St Louis, Hôpital Fernand Widal, AP-HP, Paris, France; and Pathology Department, CHU Avicenne, AP-HP, Université Paris 13, Bobigny, France BACKGROUND & AIMS: The expression of biliary lineage markers such as cytokeratin (K) 7 by hepatocytes is thought to reflect an altered regeneration pathway recruiting a stem cell compartment, more prone to carcinogenesis. We aimed to investigate the presence of these so-called intermediate hepatobiliary cells (IHC) in liver biopsies of patients with hepatitis C related cirrhosis and their potential influence on the subsequent occurrence of hepatocellular carcinoma (HCC). METHODS: From a cohort of patients with hepatitis C related cirrhosis, prospectively screened for HCC, we retrospectively selected those with a liver biopsy performed for the initial diagnosis of cirrhosis. Presence of IHC was recorded when foci of K7-positive, intermediate-sized hepatocytes were detected. RESULTS: A total of 150 patients were included (87 men; mean age, 57 y; range, y; body mass index, 25 kg/m 2 ). After a median follow-up period of 4.85 years, HCC was diagnosed in 36 patients (24%). Baseline liver biopsy showed intermediate hepatobiliary cell foci in 61 patients (41%). Intermediate cells co-expressed both hepatocytes markers and the progenitor cell markers Ep-CAM and K19. The presence of intermediate hepatobiliary cells was associated independently with HCC occurrence (Fine and Gray model; hazard ratio, 2.48; 95% confidence interval, ; P.01). Other predictors of HCC were diabetes and low platelet count. The HCC annual incidence rate was significantly higher in patients with IHC compared with patients without (8.14% vs 3.12%, Gray s test, P.003). CONCLUSIONS: The aberrant expression of biliary K by hepatocytes in patients with hepatitis C virus related cirrhosis is related independently to HCC occurrence. Keywords: Hepatocellular Carcinoma; HCV-Related Cirrhosis; Intermediate Hepatobiliary Cells; Cancer Stem Cells. Chronic hepatitis C remains a major cause of cirrhosis and hepatocellular carcinoma (HCC) in Western countries, despite the decreasing incidence of carcinoma in patients with sustained response to antiviral therapy. 1 The detection of very early and early HCC (lesion diameter, 3 cm) is of high priority because of the development of curative treatments. 2 The identification of criteria associated with a high risk of HCC occurrence could select a group that could benefit from an enhanced surveillance with improvement in mortality and cost efficiency. The currently established risk factors for HCC in compensated hepatitis C virus (HCV)-related cirrhosis include age, male sex, 3 being overweight, diabetes mellitus, 4 high -fetoprotein (AFP) serum levels, and low platelet counts. 5 Regarding histologic factors, activity, and steatosis, 6 small-cell dysplasia (SCD) and large-cell dysplasia (LCD), 7 along with hepatocyte proliferative index, 8 have shown an independent influence on HCC occurrence. In the normal adult liver, hepatocytes display a cytokeratin (K)8- and K18-positive and a K7- and K19-negative profile whereas biliary cells have a K8/18-, K7-, and K19-positive profile. In diseased liver, a ductular reaction often takes place and some intermediate hepatobiliary cells (IHC) have been described. 9 Both types of cells observed in reactive lesions, resulting from an acute or chronic liver injury, are characterized by the simultaneous expression of biliary (K7, 19, Ovalbumin-6) and hepatocyte antigens (Anti-Human Hepatocyte, K8/18, albumin). This expression of both hepatocyte and biliary lineage markers is thought to reflect an altered hepatocyte regeneration pathway recruiting a stem cell compartment, more prone to carcinogenesis as suggested by experimental models 10,11 and in vitro studies. 12,13 Although a ductular reaction is observed in almost all chronic and acute liver disease, IHC, defined as larger than 6 m and smaller than 40 m, with a dual hepatocyte and biliary Abbreviations used in this paper: AFP, -fetoprotein; Ep-CAM, epithelial cell adhesion molecular; HBV, hepatitis B virus; HCC, hepatocellular carcinama; HCV, hepatitis C virus; IHC, intermediate hepatobiliary cells; K, cytokeratin; LB, liver biopsy; LCD, large-cell dysplasia; NCAM, neural cell adhension molecule; SCD, small-cell dysplasia by the AGA Institute /$36.00 doi: /j.gastro

2 336 ZIOL ET AL GASTROENTEROLOGY Vol. 139, No. 1 expression profile, 14 have not been described thoroughly. Thus, hypothesizing the role of hepatocyte phenotypic alteration in the early steps of carcinogenesis and the potential role of progenitor cell renewal in cirrhosis, we aimed to investigate whether the presence of IHC in liver biopsies (LBs) of patients with hepatitis C related cirrhosis had an influence on the subsequent occurrence of HCC. Materials and Methods Patient Selection From a cohort of patients referred to our liver unit between January 1, 1996, and June 31, 2003 with HCV-related cirrhosis and prospectively screened for HCC detection, we selected consecutive patients for this study according to the following inclusion criteria: (1) transparietal or transjugular LB proving cirrhosis available with remaining liver tissue sample sufficient to perform subsequent immunohistochemical studies; and, at the time of liver biopsy: (2) no presence or suspicion of HCC, as judged by AFP level and ultrasonographic findings; (3) criteria for compensated cirrhosis (Child Pugh A); (4) presence of anti-hcv antibodies detectable with positive serum HCV RNA by reverse-transcription polymerase chain reaction; (5) absence of hepatitis B virus (HBV) infection, hemochromatosis, diagnosis of biliary cirrhosis, Wilson disease, -1-antitrypsin deficiency, or human immunodeficiency virus infection; (6) absence of severe life-threatening diseases; and (7) acceptance of regular follow-up evaluations and periodic HCC screening. In addition, patients who cleared HCV infection from January 1996 up to the last recorded visit in January 2008 were excluded from the study because the occurrence of HCC in these patients was proven to be decreased. 1,15 For each patient, the date of inclusion was the date of the first LB showing cirrhosis. On the day of the biopsy, the following parameters were recorded: age, sex, body mass index, diabetes status, liver tests including prothrombin activity (%), albumin level (g/l), total bilirubin level (um/l), aspartate aminotransferase level (UI/L), alanine aminotransferase level (UI/L), alkaline phosphatase level (UI/L), -glutamyl transferase level (UI/L), platelet count (/mm 3 ), and AFP level (ng/ml). The cause of cirrhosis was considered as mixed (HCV and alcohol) when patients had past or ongoing daily alcohol intake greater than 30 g/day at the time of liver biopsy. Diabetes status was collected as a binary parameter (yes/no) and was defined by a fasting serum glucose level greater than 126 mg/dl or by the use of antidiabetic drugs. Follow-Up Evaluation and HCC Assessment Patients were followed up prospectively and HCC was screened by abdominal ultrasonography and AFP level performed at least every 6 months. The diagnosis of HCC was assessed through histology (with a guided liver biopsy) or noninvasive criteria according to the recommendation of the Barcelona Conference. 16 Patients were considered lost to follow-up evaluation when absent for more than one visit for HCC screening. The main end point of the study was the occurrence of HCC. The time frame was defined as the time from the date of biopsy until the HCC occurrence. Follow-up evaluation ended at the date of HCC diagnosis, at the date of liver transplantation, at the date of death without HCC, or at the last recorded visit until January 31, Histology and Immunohistochemistry LBs from patients with hepatitis C related cirrhosis were examined for the presence of LCD and SCD according to the previously described criteria, 17 for grading activity 18 and for semiquantitative assessment of macrovesicular steatosis. In addition, we searched for the association of ballooned hepatocytes with Mallory bodies and polymorphonuclear cells to define alcoholic hepatitis. Dewaxed and rehydrated paraffin sections, 3- m thick, were immunostained with antibodies to K7, to a mixture of K8 and K18, to K19, to neural cell adhesion molecule (NCAM), to epithelial cell adhesion molecule (Ep-CAM), CD117, CD34, N-cadherin, and chromogranin as detailed in the Supplementary Materials and Methods section and Supplementary Table 1. K7 immunostained sections were assessed independently by 2 observers (M.Z., N.B.) without knowledge of the patient s outcome. The observation of at least 2 foci of more than 5 polyg- Figure 1. Description of IHC, isolated cholangiocytes, and ductular reaction on K7 immunostained LBs of patients with HCV-related cirrhosis. (A) Groups of more than 5 K7-positive cells with a polygonal cytoplasmic shape that look like hepatocytes, measuring 6 40 m, were identified as IHC, regardless of their localization (eg, close to or at a distance from fibrous septa and/or ductular reaction). (B) Isolated round small cells with high nuclear to cytoplasmic ratios were considered as isolated cholangiocytes. (C) Positive cord-like structures corresponding to ductular reaction, canal of Hering, or bile ductules were not taken into account.

3 July 2010 KERATIN 7 AND HEPATOCARCINOGENESIS 337 onal-shaped hepatocytes, measuring from 6 to 40 m large, with cytoplasmic positivity (positivity of either the whole cytoplasmic area or only the submembranous areas) defined the presence of IHC (Figure 1A). The same criteria were applied for K19 foci. The presence of small isolated positive cells distinct of cord-like structures also was reported as isolated cholangiocytes (Figure 1B). Cord-like structures were not considered (Figure 1C). In case of disagreement regarding IHC assessment, sections were re-examined using a multipipe microscope and a consensus was reached that was used for the analysis of HCC occurrence. We further investigated the expression profile of IHC on consecutive sections; K19 immunostaining was performed to investigate another biliary marker, K8 and K18, to check the conservation of hepatocyte markers, and Ep-CAM, NCAM, CD117, CD34, and chromogranin A to investigate other progenitor cell markers. Furthermore, when K7 immunostaining was positive, it was categorized as extensive staining when one or several cirrhotic nodules showed positive staining in more than 30% of the hepatocyte or categorized as focal staining in other cases. To investigate the within-biopsy reproducibility of the detection of IHC, we retrieved from our pathology files patients who had subsequent LB, either at the time of HCC diagnosis or during follow-up evaluation, and assessed the presence of IHC as described earlier without knowledge of the results of the first biopsy. Control Patients For control of cytokeratin 7 immunostaining, LBs of 28 patients with chronic hepatitis C with mild fibrosis (F1 or F2 according to the METAVIR scoring system), matched for age and sex, were selected consecutively from our pathology files. Statistical Analysis Continuous data were expressed as means standard deviation, and categoric data were reported as frequency and percentage. Continuous and qualitative data related to the presence of IHC were analyzed using the Mann Whitney test and the Fisher exact test, respectively. Because mortality related to the progression of liver disease without HCC is non-negligible in these cohorts of cirrhotic patients, we used the Fine and Gray 19 model, which extends the Cox model to competing risks data including those related to death, to determine independent factors associated with HCC occurrence. Variables Table 1. Clinical, Biological, and Histologic Characteristics of Patients With HCV-Related Cirrhosis at the Time of Inclusion According to the Presence of IHC Patient characteristics Patients selected for the study (n 150) Patients with IHC (n 61; 41%) Patients without IHC (n 89; 59%) P a Clinical characteristics Age at inclusion, y b Sex, male c 87 (58) 38 (62) 49 (55).38 Alcohol, 30 g/day c 64 (42.7) 28 (46) 36 (40).51 Body mass index, kg/m 2b Diabetes mellitus c 53 (36.3) 19 (31.7) 34 (39.5).33 Biological characteristics c Platelet count, 10 3 /mm Prothrombin time, % AFP level, ng/ml Bilirubin level, mol/l Albumin level, g/l AST level, ULN ALT level, ULN Glutamyl transferase level, ULN ALP level, ULN HCV genotype (62.3) 66 (74.2).12 Histologic characteristics LB size, mm LCD 12 (8) 5 (8.3) 7 (7.9) 1.00 Activity A2 or A3 93 (62) 41 (67.2) 52 (58.4).28 Macrovesicular steatosis, 30% 25 (17) 9 (14.8) 16 (18).6 Isolated cholangiocytes 125 (83) 60 (98.4) 65 (73) <10-4 Alcoholic hepatitis 17 (11) 8 (13) 9 (10).54 NOTE. Bold entries indicate significant differences between groups. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal. a The Fisher exact test was used for binary variables and the Mann Whitney test was used for continuous variables. b Mean value standard deviation. c Number (%).

4 338 ZIOL ET AL GASTROENTEROLOGY Vol. 139, No. 1 with a P value less than.10 in the univariate analysis were entered into a stepwise multivariate model. In addition, cumulative incidence function was computed and compared in terms of the HCC occurrence between individuals with and without IHC using the Gray 20 test. Interobserver and interbiopsy agreements were determined using the statistic. All analyses were 2-sided and differences with P values less than.05 were considered statistically significant. All statistical analyses were performed using SAS 9.2 and R 2.8 software (SAS Inc, Cary, NC). Results Baseline Patient Characteristics and HCC Occurrence A cohort of 290 patients with Child class A, HCVrelated cirrhosis was included in an HCC screening program from January 1996 to June The liver biopsy sample was available at our institution with sufficient remaining tissue for immunohistochemical analysis in 201 patients. Among them, 35 patients were excluded because of HCV infection clearing during the follow-up evaluation and 16 other patients were not studied because immunostaining was not obtained or not interpretable. Thus, 150 patients were included. Clinical, biochemical, and histologic characteristics are detailed in Table 1. The median duration of follow-up evaluation for HCC occurrence was 4.85 years. Thirty-six patients (24%) developed HCC and the incidence rate of HCC occurrence was 5% per year. Thirty-two patients were lost to follow-up evaluation before January The diagnosis of HCC was based on noninvasive criteria in 22 patients and on histology in 14 cases. During follow-up evaluation, 10 patients died of liver disease without HCC, 4 patients died of liver unrelated disease, and 3 patients were transplanted without HCC. Histology and Immunostaining Liver biopsy specimens consisted of 1 10 fragments and the sum of the length of fragments varied from 6 to 30 mm (mean standard deviation, 12 5 mm). The distribution of hepatitis activity grade and the percentage of steatosis are given in Table 1. Seventeen (11%) patients had alcoholic hepatitis. LCD was identified in 12 patients (8%), and no focus of SCD was observed. Two or more K7- or K19-positive intermediate hepatobiliary cell foci were observed in 61 cases (41%) and 43 cases (28%), respectively. The interobserver agreement for this parameter was 0.79 (confidence interval, ). As shown in Figure 2, IHC could be observed either in periseptal areas and/or in the center of the cirrhotic nodules. The amount of IHC varied from 2 isolated foci of 3 5 cells distributed throughout the biopsy to the presence of cirrhotic nodules with extensive IHC areas. K7 staining was focal in 47 cases and extensive in 14 cases. The staining was cytoplasmic with a strong peripheral submembranous reinforcement or only submembranous with a clear perinuclear area giving a honeycomblike pattern. Isolated cholangiocytes were observed in 60 cases positive for intermediate cells and the 2 types of cells Figure 2. (A F) Representative samples of the distribution of IHC in HCV-related cirrhosis. (A and B) K7 decorated bile duct (black arrows) and (A C) ductular reaction (white arrows) in all HCV-related cirrhosis and served as a positive internal control for this immunostaining. (A and D) In most cases, no IHC or isolated cholangiocyte was observed in cirrhotic nodules. When present, IHC foci were rare and barely detectable at (B) low-power field (black arrowheads) or(c) formed confluent zones (defined as an extensive staining) with a percentage of positive hepatocyte reaching 30% (black arrowheads). At a higher magnification (D F are located in A C, respectively), (E and F) IHC displayed a cytoplasmic positivity with a strong submembranous reinforcement (black arrows). (E and F) Isolated cholangiocytes frequently were observed in the vicinity of positive intermediate cells (white arrows) and showed a strong cytoplasmic staining without submembranous reinforcement.

5 July 2010 KERATIN 7 AND HEPATOCARCINOGENESIS 339 Figure 3. Complementary analysis of the staining pattern of IHC. At an intermediate (200 ) and high magnification (1000 ; inset), the immunostaining performed on consecutive sections showed that the foci of K7 IHC corresponded to foci positive for K19, another biliary marker, and Ep-CAM, a marker of progenitor cells. As indicated by black arrows, the foci of positive hepatocytes were detectable on these 3 different immunostainings. However, some differences were observed because membranous Ep CAM staining generally encompassed the K7 stained areas and also was shown, albeit more slightly, in other areas negative for K7 (star). K19 immunostained the foci of K7 positive hepatocytes, but to a lesser extent, with a few cells at the periphery of foci being K7-positive and K19-negative. These K7/K19 foci retained a high expression of K8 and 18. NCAM was not expressed. No peculiar feature was observed on routine staining. colocalized as shown in Figure 2. In addition, 65 patients LBs showed isolated cholangiocytes without intermediate cells. LCD foci did not include any intermediate hepatocyte or isolated cholangiocyte. Examination of serial sections, as illustrated in Figure 3, disclosed that intermediate cells all were positive for K8/K18. Most of the cells positive for K7 also were positive for K19, but to a lesser extent with a few cells at the periphery of foci, being K7-positive and K19-negative. They also constantly were positive for Ep-CAM, known as a hepatocyte progenitor cell marker. However, membranous Ep-CAM staining generally encompassed the K7 stained areas and also was shown, albeit more slightly, in other areas negative for K7. IHC and isolated cholangiocytes were negative for the other progenitor cell markers such as CD34, CD117, NCAM, and chromogranin. With the exception of 2, all LBs from the 28 patients with chronic hepatitis C and low fibrosis (F1 or F2 according to METAVIR scoring system) were negative for either IHC or isolated cholangiocytes. One of the 2 positives cases showed obvious alcoholic hepatitis with Mallory bodies and polymorphonuclear infiltrate, a condition known to be associated with K7 positivity. 21 Thirty of the 150 patients have had a subsequent LB available for immunostaining (8 at the time of HCC diagnosis; 22 without evidence of HCC) with a mean delay between the 2 LBs of 2.4 years (6 mo to 7 y). In 25 cases (83%), the results of both biopsies were in agreement and the calculated coefficient showed a good agreement (, 0.67; confidence interval, ) for the detection of IHC in sequential biopsies. Characteristics Associated With the Detection of IHC in Liver Biopsy The baseline characteristics are detailed in Table 1. Patients with IHC had a significantly lower platelet count and prothrombin time than patients without IHC. Among 36 patients who developed HCC, 22 had IHC (61%), whereas in the 114 patients without HCC, 39 had IHC (34%). In univariate analysis, clinical, biological, and histologic variables at inclusion that significantly affected the occurrence of HCC were as follows (Table 2): the presence of IHC (assessed by K7 or K19 immunostaining, either focal or extensive immunostaining), diabetes, platelet counts, and body mass index. Age, sex, histologic alcoholic hepatitis or alcohol consumption greater than 30 g/day, and LCD were not associated with HCC occurrence. Among these parameters, multivariate analysis using the Fine and Gray 19 model showed that the presence of IHC assessed by K7, diabetes, and a low platelet count remained independently related to the development of HCC. As shown in Figure 4, the HCC annual incidence rate was significantly higher in patients with K7 IHC compared with patients without IHC (8.14% vs 3.12%; Gray s test, P.003) as well as in patients with K19 IHC (10.1%

6 340 ZIOL ET AL GASTROENTEROLOGY Vol. 139, No. 1 Table 2. Clinical, Biological, and Histologic Characteristics Associated With the Risk of HCC Occurrence According to the Fine and Gray Model Univariate analysis Multivariate analysis HR (95%) P HR (95%) P Clinical data Male sex ( ).637 Alcohol, 30 g/day ( ).746 Age, y ( ).139 Diabetes mellitus ( ) ( ).001 Body mass index, kg/m ( ).034 Biological data Platelet count, 10 3 /mm ( ) ( ).014 Prothrombin time, % ( ).953 AFP level, ng/ml ( ).119 ALT level, ULN ( ).339 AST level, ULN ( ).201 Bilirubin level, mol/l ( ).540 ALP level, ULN ( ).276 GGT level, ULN ( ).892 Albumin level, g/l ( )].440 HCV genotype ( ).198 Histologic data IHC (K7 extensive or focal) ( ) ( ).010 Extensive staining ( ).02 Focal staining ( ).0097 IHC (K19) ( ).0036 Isolated cholangiocytes ( ).679 Activity A2/A ( ).308 Macrovesicular steatosis, 30% ( ).096 LCD ( ).913 Alcoholic hepatitis ( ).329 ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, -glutamyl transferase; HR, hazard ratio; ULN, upper limit of normal. vs 3.6%; Gray s test, P.003). When only patients with extensive areas of IHC were considered (n 14), the HCC annual incidence rate was 10.6% vs 4.6% in patients without or with focal staining (Gray s test, P.091). Discussion In this cohort of patients with compensated HCVrelated cirrhosis prospectively screened for HCC, the detection of IHC in the baseline liver biopsy was a strong and independent risk factor for HCC occurrence (hazard ratio, 2.483; confidence interval, ). We describe the distribution and the frequency of hepatocyte foci with an aberrant immunophenotype close to that observed in progenitor cells, in the biopsies of patients with HCV-related cirrhosis, and establish a link between its detection and the risk of developing HCC. This finding raises concerns regarding the early steps of carcinogenesis in cirrhosis and perspectives for focusing HCC screening in a high-risk population. The influence of K expression profile of nontumoral liver on subsequent HCC development could be supported indirectly by some previous studies. SCD is considered a preneoplastic lesion because of genetic alterations 22 and high proliferative rates. 23 However, the value of SCD in predicting HCC is impaired by its low frequency in LB 8,24,25 and conflicting results with no independent association with HCC in several studies, 7,24,25 although having independent influence in others. 26 Moreover, these foci are difficult to detect and the interobserver agreement for SCD has not been reported. We did not observe any SCD in our study, but foci of intermediate hepatocytobiliary cells showed small-sized hepatocytes with a slightly increased nuclear to cytoplasmic ratio. In addition, 55% of SCD foci have been shown to notably consist of intermediate cells expressing K7, K8, and K Thus, IHC foci that we detected immunohistochemically with a very good interobserver agreement could represent early foci of SCD, more frequently sampled on LB and undetectable on routinely stained sections. A recent study 28 disclosed that gene expression profiles of HCC failed to yield a significant association with survival, whereas surrounding nontumoral profiles correlated with recurrence. K7 was one of the genes of this recurrence signature. Our study was not designed to investigate survival but, in line with these results, we found a relationship between altered K expression profile in nontumoral livers and subsequent HCC occurrence. In the normal human adult liver, mature hepatocytes proliferate whereas in chronic liver disease a reserve compartment of hepatic progenitor cells is activated. 29 These cells are identified morphologically as ductular reaction and

7 July 2010 KERATIN 7 AND HEPATOCARCINOGENESIS 341 Figure 4. Outcome of patients with HCVrelated cirrhosis according to the presence of IHC on nontumoral liver biopsy. The cumulative curves of the incidence of HCC are adjusted for competing risk and compared according to the Gray test. 35 The numbers of patients at risk are indicated under the x-axis. The HCC incidence rates were significantly higher in patients with (A) K7or(B) K19 IHC compared with patients without (8.14% vs 3.12% per year, P.003; and 10.1% vs 3.6%, P.003, respectively). (C) When the extent of K7 hepatobiliary cells was taken into account, the incidence of HCC was higher in patients with extensive areas of IHC compared with other patients (10.6% vs 4.6%; P.01). IHC, and they expressed markers of both hepatocytic and biliary lineage. 9 This altered type of renewal is observed in chronic hepatitis C 30 as a function of activity and fibrosis. Given the direct evidence for the involvement of progenitor cells in the genesis of HCC in experimental models 31 with the identification of human HCC expressing progenitor cell markers such as K7 and K19, 32 it is hypothesized that in human beings chronic hepatocellular injury favors the

8 342 ZIOL ET AL GASTROENTEROLOGY Vol. 139, No. 1 emergence of phenotypically altered cells resistant to cytotoxicity and growth arrest. 31 We provide here some basis to confirm this hypothesis by showing an independent relation between the presence of phenotypically altered cell foci and occurrence of HCC. Whether these intermediate cell foci represent true preneoplastic lesions with genetic alterations and clonality as it was shown for SCD 22,33 was not addressed in the present study. Further studies, which would be performed more easily on cirrhotic explanted livers with or without HCC, are needed to characterize these intermediate cells and identify potential markers that could be targeted specifically by therapy, especially including Ep-CAM. 34 We found that 41% of patients with HCV-related cirrhosis had IHC. Similar foci have been described in alcoholic and nonalcoholic fatty liver diseases, 29,35 in cirrhotic nodules adjacent to HCC in HBV patients, 36 and in cholestatic liver disease, 37 but its frequency in HCV-related cirrhosis and potential clinical significance has not been reported. The high frequency of IHC in our patients with HCV cirrhosis differed from its nearly complete absence in the large biopsy samples of patients with low fibrosis stages of chronic hepatitis C. This finding reinforces its potential value in helping to define high-risk patients. If some foci of ballooned hepatocytes were positive for K7, a significant relation was not found between the presence of alcoholic hepatitis, alcohol consumption, or steatosis and the finding of IHC. Whether these intermediate cells derive from progenitor cells or result from the transdifferentiation of mature hepatocyte into biliary cells as shown in animal models 38 and hepatoma cell lines 39 cannot be determined by this observational study. However, by using serial immunostaining, we showed that the intermediate cells expressed, as summarized recently, 40 some of the markers of progenitor cells such as Ep-CAM, K7, and K19, but did not express other potential stem cell markers such as NCAM, CD117, chromogranin, and CD34. Isolated cholangiocytes did not express NCAM, CD117, chromogranin, or CD34. Interestingly, IHC were observed in all cases in continuity with isolated cholangiocytes (Figure 3) that represent the progenitor cell compartment of normal liver. 9 This colocalization, along with the strong association between the detection of both types of cells, could favor the hypothesis that intermediate cells derive from isolated cholangiocytes. In contrast, intermediate cells were not observed in continuity with the ductular reaction that always was represented to a variable extent at the interface between fibrous septa and hepatocyte, and some large hepatocytes ( 40 m) also expressed K7. Thus, IHC do not appear to derive from the ductular reaction and also could represent a gradual phenotypic change from mature hepatocytes negative for biliary markers to hepatocytes expressing K7, then K19, and, finally, to progenitor cells. Identification of an immunohistochemical marker, associated with an increased risk of developing HCC, also could yield clinical applications because the relative risk was equal to 2 although no other clinical or biological parameter except diabetes mellitus and low platelet count was proved to have an independent influence on HCC development. In practice, this immunohistochemical characteristic can be determined retrospectively as part of a routine examination with low cost and a good interobserver agreement. Our findings need confirmation in other cohorts because this preliminary study was monocentric but the presence of intermediate cells on baseline liver biopsy, in combination with other clinical and biological criteria, efficiently could help to design a group of patients with a high risk of developing HCC. The univariate analysis did not identify the traditional risk factors such as age and male sex 41 for HCC occurrence in our 150 patients but it has been reported previously in studies including fewer than 200 patients. 42,43 We also found a higher incidence of HCC (5% per year) compared with that reported in other studies, 41 with frequencies ranging in Western patients from 1.5% to 4.6%. This is linked to the exclusion of cirrhotic patients who achieved HCV clearance during the follow-up evaluation for HCC, although most studies did not exclude these patients. 3,42,43 Patients who cleared HCV were excluded because we considered that it was an event occurring during the follow-up period, shown to significantly affect the risk of HCC. 15 In conclusion, we found a significant and independent association between the detection of IHC foci, identified with a good interobserver agreement using K7 immunostaining in nontumoral LB, and HCC occurrence in HCVrelated cirrhosis. These findings suggest that the acquisition of an aberrant cytokeratin expression profile by some hepatocytes could represent an early stage of carcinogenesis in cirrhosis that would be targeted and could help define patients with HCV-related cirrhosis at high risk for developing HCC. Supplementary Material Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at and at doi: /j.gastro References 1. Camma C, Giunta M, Andreone P, et al. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34: El-Serag HB, Marrero JA, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134: Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000;47: N Kontchou G, Paries J, Htar MT, et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 2003;4:

9 July 2010 KERATIN 7 AND HEPATOCARCINOGENESIS Rodríguez-Díaz JL, Rosas-Camargo V, Vega-Vega O, et al. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study. Clin Oncol 2007;19: Pekow JR, Bhan AK, Zheng H, et a. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007;109: Ganne-Carrié N, Chastang C, Chapel F, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology 1996;23: Donato MF, Arosio E, Del Ninno E, et al. High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity. Hepatology 2001;34: Roskams TA, Theise ND, Balabaud C, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004;39: Thorgeirsson SS, Factor VM, Snyderwine EG. Transgenic mouse models in carcinogenesis research and testing. Toxicol Lett 2000;15: Libbrecht L, Meerman L, Kuipers F, et al. Liver pathology and hepatocarcinogenesis in a long-term mouse model of erythropoietic protoporphyria. J Pathol 2003;199: Cerec V, Glaise D, Garnier D, et al. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 2007;45: Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132: Roskams T. Different types of liver progenitor cells and their niches. J Hepatol 2006;45: Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008;149: Bruix J, Sherman M, Llovet J, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001;35: Watanabe S, Okita K, Harada T, et al. Morphologic studies of the liver cell dysplasia. Cancer 1983;51: The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20: Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94: Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16: Crosby HA, Hubscher S, Fabris L, et al. Immunolocalization of putative human liver progenitor cells in livers from patients with endstage primary biliary cirrhosis and sclerosing cholangitis using the monoclonal antibody OV-6. Am J Pathol 1998;152: Marchio A, Terris B, Meddeb M, et al. Chromosomal abnormalities in liver cell dysplasia detected by comparative genomic hybridisation. Mol Pathol 2001;54: Adachi E, Hashimoto H, Tsuneyoshi M. Proliferating cell nuclear antigen in hepatocellular carcinoma and small cell liver dysplasia. Cancer 1993;72: Libbrecht L, Craninx M, Nevens F, et al. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 2001;39: Brunt EM, Walsh SN, Hayashi PH, et al. Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma. Liver Int 2007;27: Makino Y, Shiraki K, Sugimoto K, et al. Histological features of cirrhosis with hepatitis C virus for prediction of hepatocellular carcinoma development; a prospective study. Anticancer Res 2000;20: Libbrecht L, Desmet V, Van Damme B, et al. The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J Hepatol 2000;33: Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359: Roskams T, Yang SQ, Koteish A, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003;163: Clouston AD, Powell EE, Walsh MJ, et al. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005;4: Marongiu F, Doratiotto S, Montisci S, et al. Liver repopulation and carcinogenesis: two sides of the same coin? Am J Pathol 2008; 172: Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006;49: Terris B, Ingster O, Rubbia L, et al. Interphase cytogenetic analysis reveals numerical chromosome aberrations in large liver cell dysplasia. J Hepatol 1997;27: Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009;136: Lackner C, Gogg-Kamerer M, Zatloukal K, et al. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 2008;48: Xiao JC, Jin XL, Ruck P, et al. Hepatic progenitor cells in human liver cirrhosis: immunohistochemical, electron microscopic and immunofluorescence confocal microscopic findings. World J Gastroenterol 2004;10: Crosby HA, Hubscher S, Fabris L, et al. Immunolocalization of putative human liver progenitor cells in livers from patients with endstage primary biliary cirrhosis and sclerosing cholangitis using the monoclonal antibody OV-6. Am J Pathol 1998;152: Michalopoulos GK, Barua L, Bowen WC. Transdifferentiation of rat hepatocytes into biliary cells after bile duct ligation and toxic biliary injury. Hepatology 2005;41: Cerec V, Glaise D, Garnier D, et al. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 2007;45: Mishra L, Banker T, Murray J, et al. Liver stem cells and hepatocellular carcinoma. Hepatology 2009;49: Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127:S35 S Serfaty L, Aumaître H, Chazouillères O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27: Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006;43: Received July 15, Accepted April 12, Reprint requests Address requests for reprints to: Marianne Ziol, MD, PhD, Pathology Department, CHU Jean Verdier, Paris 13 University, Av du 14 Juillet, Bondy, France. fax: (33) Conflicts of interest The authors disclose no conflicts.

10 343.e1 ZIOL ET AL GASTROENTEROLOGY Vol. 139, No. 1 Supplementary Materials and Methods Immunohistochemistry Dewaxed and rehydrated paraffin sections, 3- m thick, were immunostained with antibodies to K7, to a mixture of K8 and K18, to K19, NCAM, Ep-CAM, CD117, CD34, N-cadherin, and chromogranin. The clone number, provider, antigen retrieval, and dilution used for these antibodies are detailed in Supplementary Table 1. All immunostaining was performed as previously described using an automated immunostaining device (Vision Biosystem Bond Max, Menarini, France). After heatinduced antigen retrieval (Vision BioSystems ER1) for 20 minutes at a ph of 8, sections were incubated with the primary antibody for 30 minutes and immunodetection was performed with a biotin-conjugated secondary antibody (Vision BioSystems DS9713) followed by peroxidase-labeled streptavidin and with 3,3=-diaminobenzidine tetrahydrochloride chromogen as the substrate (Vision BioSystems).

11 July 2010 KERATIN 7 AND HEPATOCARCINOGENESIS 343.e2 Supplementary Table 1. Summary of the Primary Antibodies Used for Immunohistochemistry Antibody directed against Used as a marker for Official gene symbol Identification Antibody clone Isotype Dilution Supplier K7 Intermediate hepatocytes KRT OV-TL 12/30 IgG1 1:800 DAKO, Glastrup, Denmark K19 Intermediate hepatocytes KRT BA17 IgG1 1/200 DAKO K8 Hepatocyte and biliary cells KRT8 16,691 35betaH11 IgGM Prediluted DAKO K18 Hepatocyte and biliary cells KRT DC10 IgG1 1/25 DAKO NCAM Progenitor cells NCAM CD564 IgG2b 1/200 Novocastra, Newcasatle, United Kingdom Ep-CAM Progenitor cells EPCAM 4072 BerEP4 IgG1 1/50 DAKO CD117 Progenitor cells KIT 3815 Polyclonal 1/200 DAKO CD34 Progenitor cells CD QBEND10 IgG1 1/200 DAKO Chromogranin Progenitor cells CHGA 1113 LK2H10 IgG1 1/20 Beckman, Marsceilles, France Ig, immunoglobulin.

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor

More information

Pitfalls in the diagnosis of well-differentiated hepatocellular lesions

Pitfalls in the diagnosis of well-differentiated hepatocellular lesions 2013 Colorado Society of Pathology Pitfalls in the diagnosis of well-differentiated hepatocellular lesions Sanjay Kakar, MD University of California, San Francisco Outline Hepatocellular adenoma: new WHO

More information

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis

More information

The role of Hepatitis C Virus in hepatocarcinogenesis

The role of Hepatitis C Virus in hepatocarcinogenesis The role of Hepatitis C Virus in hepatocarcinogenesis Laura Beretta Fred Hutchinson Cancer Research Center l8 Incidence and mortality of the five most common cancers worldwide, 2000 Incidence Lung Breast

More information

ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche,

ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche, Supplemental Methods Analytical determinations ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche, Basel, Switzerland). Glucose, triglyceride, total

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C

More information

Monitoring Hepatitis C

Monitoring Hepatitis C Monitoring Hepatitis C Section Six Monitoring Hepatitis C Screening for hepatitis C is not routinely done, so you may have to request a test from your medical provider. This usually involves an antibody

More information

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

2. Liver blood tests and what they mean p2 Acute and chronic liver screen Hepatology referral pathways for GP 1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for hepatology referral 3. Raised

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function

More information

Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview.

Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview. Review Med Ultrason 2014, Vol. 16, no. 2, 139-144 DOI: Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview. Mirela Dănilă, Ioan Sporea Gastroenterology

More information

In Western countries, hepatocellular carcinoma

In Western countries, hepatocellular carcinoma HEAPTOBILIARY MALGINANCIES Ultrasonographic Surveillance of Hepatocellular Carcinoma in Cirrhosis: A Randomized Trial Comparing 3- and 6-Month Periodicities Jean-Claude Trinchet, 1,2 Cendrine Chaffaut,

More information

Slide 7 demonstrates acute pericholangitisis with neutrophils around proliferating bile ducts.

Slide 7 demonstrates acute pericholangitisis with neutrophils around proliferating bile ducts. Many of the histologic images and the tables are from MacSween s Pathology of the Liver (5 th Edition). Other images were used from an online source called PathPedia.com. A few images from other sources

More information

Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France

Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France 9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures

More information

Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice

Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College

New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College New insights into fatty liver disease Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Prevalence of NASH Global prevalence of NAFLD is 25% with highest prevalence in the Middle

More information

Surveillance for Hepatocellular Carcinoma

Surveillance for Hepatocellular Carcinoma Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April

More information

Interpreting Liver Function Tests

Interpreting Liver Function Tests PSH Clinical Guidelines Statement 2017 Interpreting Liver Function Tests Dr. Asad A Chaudhry Consultant Hepatologist, Chaudhry Hospital, Gujranwala, Pakistan. Liver function tests (LFTs) generally refer

More information

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di

More information

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,

More information

Dhanpat Jain Yale University School of Medicine, New Haven, CT

Dhanpat Jain Yale University School of Medicine, New Haven, CT Dhanpat Jain Yale University School of Medicine, New Haven, CT Case history 15 years old female presented with fatigue. Found to have features suggestive of cirrhosis with esophageal varices, splenomegaly

More information

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research

More information

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:989 994 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Level of -Fetoprotein Predicts Mortality Among Patients With Hepatitis C Related Hepatocellular

More information

Hepatocellular Carcinoma (HCC): Burden of Disease

Hepatocellular Carcinoma (HCC): Burden of Disease Hepatocellular Carcinoma (HCC): Burden of Disease Blaire E Burman, MD VM Hepatology Hepatocellular Carcinoma (HCC) Primary HCCs most often arise in the setting of chronic inflammation, liver damage, and

More information

Oval Cell Numbers in Human Chronic Liver Diseases Are Directly Related to Disease Severity

Oval Cell Numbers in Human Chronic Liver Diseases Are Directly Related to Disease Severity American Journal of Pathology, Vol. 154, No. 2, February 1999 Copyright American Society for Investigative Pathology Oval Cell Numbers in Human Chronic Liver Diseases Are Directly Related to Disease Severity

More information

Laboratory and Clinical Diagnosis of HCV Infection

Laboratory and Clinical Diagnosis of HCV Infection Laboratory and Clinical Diagnosis of HCV Infection Jean-Michel Pawlotsky,, MD, PhD Department of Virology (EA 3489) Henri Mondor Hospital University of Paris XII Créteil,, France I Nonspecific Liver Tests

More information

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &

More information

Liver transplantation: Hepatocellular carcinoma

Liver transplantation: Hepatocellular carcinoma Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona

More information

Diagnosis and Management of PBC

Diagnosis and Management of PBC Diagnosis and Management of PBC Cynthia Levy, MD, FAASLD University of Miami Miller School of Medicine Miami, Florida 1 Primary Biliary Cholangitis (PBC) Chronic cholestatic liver disease Autoimmune in

More information

GI Workshop Case Studies

GI Workshop Case Studies GI Workshop Case Studies Cliff Titcomb MD Hannover Re AAIM Annual Meeting San Diego, October, 2012 5 Tests Commonly Known as Liver Function Tests Alanine Aminotransferase (ALT, SGPT) Aspartate Aminotransferase

More information

Hwajeong Lee, MD, Robert T. Stapp, DO, Adrian H. Ormsby, MD, and Veena V. Shah, MD

Hwajeong Lee, MD, Robert T. Stapp, DO, Adrian H. Ormsby, MD, and Veena V. Shah, MD Anatomic Pathology / Overlap Syndrome The Usefulness of IgG and IgM Immunostaining of Periportal Inflammatory Cells (Plasma Cells and Lymphocytes) for the Distinction of Autoimmune Hepatitis and Primary

More information

Transient elastography is a new tool for assessing. Assessment of Biliary Fibrosis by Transient Elastography in Patients With PBC and PSC

Transient elastography is a new tool for assessing. Assessment of Biliary Fibrosis by Transient Elastography in Patients With PBC and PSC Assessment of Biliary Fibrosis by Transient Elastography in Patients With PBC and PSC Christophe Corpechot, 1 Ahmed El Naggar, 1 Armelle Poujol-Robert, 1 Marianne Ziol, 2 Dominique Wendum, 3 Olivier Chazouillères,

More information

Disclosure. Evaluation of Abnormal Hepatic Enzymes

Disclosure. Evaluation of Abnormal Hepatic Enzymes Evaluation of Abnormal Hepatic Enzymes Bruce D. Askey, MS, ANP-BC Associate Lecturer North Andover, MA Adult Nurse Practitioner Dept. of Hepatology/Gastroenterology Guthrie Clinic Sayre, Pa Disclosure

More information

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017 CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017 I HAVE NOTHING TO DISCLOSE Linda Ferrell PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES Linda Ferrell, MD, UCSF THE PROBLEM

More information

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic

More information

Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement

Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Fabien Zoulim Service d hépatologie, Hospices Civils de Lyon INSERM U1052, Cancer

More information

L iver steatosis is a frequent histological finding in patients

L iver steatosis is a frequent histological finding in patients 420 LIVER Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis L Castéra, C Hézode,

More information

Challenges in the Diagnosis of Steatohepatitis

Challenges in the Diagnosis of Steatohepatitis The Bugaboos of Fatty Liver Disease: Ballooning and Fibrosis Hans Popper Hepatopathology Society Companion Meeting San Antonio, Tx March, 2017 David Kleiner, M.D., Ph.D. NCI/Laboratory of Pathology Challenges

More information

Gang Huang, MD; Wan Yee Lau, MD, FRCS; Wei-ping Zhou, MD, PhD; Feng Shen, MD, PhD; Ze-ya Pan, MD; Sheng-xian Yuan, MD; Meng-chao Wu, MD

Gang Huang, MD; Wan Yee Lau, MD, FRCS; Wei-ping Zhou, MD, PhD; Feng Shen, MD, PhD; Ze-ya Pan, MD; Sheng-xian Yuan, MD; Meng-chao Wu, MD Research Original Investigation Prediction of Hepatocellular Carcinoma Recurrence in Patients With Low Hepatitis B Virus DNA Levels and High Preoperative Hepatitis B Surface Antigen Levels Gang Huang,

More information

Relationship between Serum Iron Indices and Hepatic Iron Quantitation in Patients with Fatty Liver Disease

Relationship between Serum Iron Indices and Hepatic Iron Quantitation in Patients with Fatty Liver Disease International Journal of Business, Humanities and Technology Vol. 2 No. 5; August 2012 Relationship between Serum Iron Indices and Hepatic Iron Quantitation in Patients with Fatty Liver Disease Dr. Mariana

More information

Hepatocellular Carcinoma: Epidemiology and Screening

Hepatocellular Carcinoma: Epidemiology and Screening Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman

More information

Steatohepatitic Hepatocellular Carcinoma, a Morphologic Indicator of Associated Metabolic Risk Factors

Steatohepatitic Hepatocellular Carcinoma, a Morphologic Indicator of Associated Metabolic Risk Factors Steatohepatitic Hepatocellular Carcinoma, a Morphologic Indicator of Associated Metabolic Risk Factors A Study From India Deepali Jain, MD, DNB; Nabeen C. Nayak, MD, FRCPath; Vinay Kumaran, MS, MCh; Sanjiv

More information

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none

More information

Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen

Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:889 893 Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen MYRON JOHN TONG,*, MICHAEL ONG NGUYEN, LORI TERESE TONG,

More information

Evaluation of Liver Mass Lesions. American College of Gastroenterology 2013 Regional Postgraduate Course

Evaluation of Liver Mass Lesions. American College of Gastroenterology 2013 Regional Postgraduate Course Evaluation of Liver Mass Lesions American College of Gastroenterology 2013 Regional Postgraduate Course Lewis R. Roberts, MB ChB, PhD Division of Gastroenterology and Hepatology Mayo Clinic College of

More information

Differential diagnosis of HCC

Differential diagnosis of HCC Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis

More information

PBC features and management in the era of UDCA and Budesonide

PBC features and management in the era of UDCA and Budesonide PBC features and management in the era of UDCA and Budesonide Raoul Poupon, MD Université P&M Curie, AP-Hôpitaux de Paris, Inserm, Paris, France The changing pattern of PBC Over the last 2 decades: More

More information

in liver pathology? 2014 What s hot

in liver pathology? 2014 What s hot Medizinische Fakultät Institut für Pathologie BSG Annual Liver Pathology Update Meeting Stratford upon Avon 20 November 2014 2014 What s hot in liver pathology? Dina G. Tiniakos Dept of Cellular Pathology,

More information

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas Jose D Sollano, MD Professor of Medicine Manila, Philippines International Variation in Age-Standardized Liver Cancer Incidence Rates in Both Sexes, 2008 Global Age-Standardized Liver Cancer Incidence

More information

9th Paris Hepatitis Conference

9th Paris Hepatitis Conference 9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units

More information

Xiao-Ling Chi, Mei-Jie Shi, Huan-Ming Xiao, Yu-Bao Xie, and Gao-Shu Cai. Correspondence should be addressed to Xiao-Ling Chi;

Xiao-Ling Chi, Mei-Jie Shi, Huan-Ming Xiao, Yu-Bao Xie, and Gao-Shu Cai. Correspondence should be addressed to Xiao-Ling Chi; Evidence-Based Complementary and Alternative Medicine Volume 2016, Article ID 3743427, 6 pages http://dx.doi.org/10.1155/2016/3743427 Research Article The Score Model Containing Chinese Medicine Syndrome

More information

Viral Hepatitis (I) Luigi Terracciano Department of Pathology University Hospital Basel. Basel,

Viral Hepatitis (I) Luigi Terracciano Department of Pathology University Hospital Basel. Basel, Viral Hepatitis (I) Luigi Terracciano Department of Pathology University Hospital Basel Basel, 19. 04. 2016 Definition Hepatitis means inflammation of the liver characterized by a variable combination

More information

Update on HIV-HCV Epidemiology and Natural History

Update on HIV-HCV Epidemiology and Natural History Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,

More information

ANRS CO12 CIRVIR - Prospective cohort involving patients with viral cirrhosis B and C

ANRS CO12 CIRVIR - Prospective cohort involving patients with viral cirrhosis B and C ANRS CO12 CIRVIR - Prospective cohort involving patients with viral cirrhosis B and C Head : Nahon Pierre, Service d'hépatologie, Hôpital Jean Verdier Roudot-thoraval Françoise, Service de santé publique,

More information

There are approximately 1 million new cases of primary hepatocellular

There are approximately 1 million new cases of primary hepatocellular CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:800 806 Liver Transplantation in Patients With Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma SHAHID M. MALIK,* PARIJAT A. GUPTE,* MICHAEL

More information

Applied Health Economics and Health Policy

Applied Health Economics and Health Policy Applied Health Economics and Health Policy Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal Elamin H. Elbasha, Jagpreet Chhatwal,

More information

Single and Multiplex Immunohistochemistry

Single and Multiplex Immunohistochemistry Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch

More information

C hronic hepatitis B (CHB) virus infection affects more

C hronic hepatitis B (CHB) virus infection affects more 161 HEPATITIS Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications MF Yuen, HJ Yuan, D KH Wong, J CH Yuen, WM Wong, A OO Chan, B CY Wong, KC Lai, CL Lai... See end of article

More information

NON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN

NON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN NON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN M. Beaugrand Service d Hépatologied Hopital J. Verdier BONDY 93143 et Université Paris XIII MAINZ 21.09.2008 ASSESSMENT OF FIBROSIS : WHY? Management

More information

Patients with compensated cirrhosis: how to treat and follow-up

Patients with compensated cirrhosis: how to treat and follow-up Patients with compensated cirrhosis: how to treat and follow-up Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Universitätsklinikum Leipzig Leber- und Studienzentrum

More information

Choosing the best treatment for HCC using Albumin-Bilirubin score. Paul BS LAI Department of Surgery The Chinese University of Hong Kong

Choosing the best treatment for HCC using Albumin-Bilirubin score. Paul BS LAI Department of Surgery The Chinese University of Hong Kong Choosing the best treatment for HCC using Albumin-Bilirubin score Paul BS LAI Department of Surgery The Chinese University of Hong Kong Many HCC patients have cirrhosis And the liver function or liver

More information

Acute Hepatitis in a Patient with NASH and Elevation of CMV-IgM

Acute Hepatitis in a Patient with NASH and Elevation of CMV-IgM Acute Hepatitis in a Patient with NASH and Elevation of CMV-IgM Uta Drebber, MD Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the

More information

Novedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona

Novedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir

More information

Biochemical Investigations in Liver Disease. Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya

Biochemical Investigations in Liver Disease. Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya Biochemical Investigations in Liver Disease Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya Biochemical markers Albumin ALP ALT, AST Gamma-glutamyl transpeptidase

More information

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center

More information

ONCOLOGY REPORTS 30: 91-98, 2013

ONCOLOGY REPORTS 30: 91-98, 2013 ONCOLOGY REPORTS 30: 91-98, 2013 Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma HIROKI

More information

Waseem Hamoudi MD*, Sami Al-Smadi MD*, Karim Lutfi MD*, Moath Azizi MD*, Yousef Niomat MD* ABSTRACT

Waseem Hamoudi MD*, Sami Al-Smadi MD*, Karim Lutfi MD*, Moath Azizi MD*, Yousef Niomat MD* ABSTRACT Durability of Sustained Virological Response and Long Term Follow Up To Pegylated Interferon and Ribavirin in Treated Patients with Chronic Hepatitis C Waseem Hamoudi MD*, Sami Al-Smadi MD*, Karim Lutfi

More information

OPEN.

OPEN. www.nature.com/scientificreports Received: 9 February 2017 Accepted: 14 August 2017 Published: xx xx xxxx OPEN Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma

More information

Hepatitis C wi w t i h Ju J dy y W y W a y t a t t

Hepatitis C wi w t i h Ju J dy y W y W a y t a t t Hepatitis C with Judy Wyatt Hepatitis C and the histopathologist Pre-2006 biopsy based treatment of moderate-severe chronic hepatitis Now biopsy for: Watchful waiting, to confirm mild disease? Cirrhosis

More information

MRI for HCC surveillance and reporting: LI-RADS. Donald G. Mitchell, M.D. Thomas Jefferson University Philadelphia, PA

MRI for HCC surveillance and reporting: LI-RADS. Donald G. Mitchell, M.D. Thomas Jefferson University Philadelphia, PA MRI for HCC surveillance and reporting: LI-RADS Donald G. Mitchell, M.D. Thomas Jefferson University Philadelphia, PA Cirrhotic Nodules Regenerative Nodule Atypical Nodule Hyperplastic Nodule Dysplastic

More information

Case Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation

Case Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation 108 Diagnostic Problems in Hepatology Case Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation Brian Kim, MD 1 Anshu Trivedi, MD

More information

Explain the laboratory diagnosis of Rabies?

Explain the laboratory diagnosis of Rabies? Explain the laboratory diagnosis of Rabies? The standard test for rabies testing is dfa. This test has been thoroughly evaluated for more than 40 years, and is recognized as the most rapid and reliable

More information

Disclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease

Disclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease Smash the Nash: A practical approach to fatty liver disease Bruce D. Askey, MS, ANP-BC Associate Lecturer North Andover, MA Adult Nurse Practitioner Dept. of Hepatology/Gastroenterology Guthrie Clinic

More information

White Nights of Hepatology 2016

White Nights of Hepatology 2016 White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow

More information

CHAPTER 1. Alcoholic Liver Disease

CHAPTER 1. Alcoholic Liver Disease CHAPTER 1 Alcoholic Liver Disease Major Lesions of Alcoholic Liver Disease Alcoholic fatty liver - >90% of binge and chronic drinkers Alcoholic hepatitis precursor of cirrhosis Alcoholic cirrhosis end

More information

Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta )

Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta ) Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta ) Giovanni Raimondo Epatologia Clinica e Biomolecolare Policlinico Universitario di Messina UI/ml pg/ml HBsAg HBeAg + anti-hbe

More information

Alam MM 1, Mahtab MA 1, Akbar SMF 2, Kamal M 3, Rahman S 1

Alam MM 1, Mahtab MA 1, Akbar SMF 2, Kamal M 3, Rahman S 1 Bangladesh Med Res Counc Bull 2014; 40: 92-56 Hepatic necroinflammation and severe liver fibrosis in patients with chronic hepatitis B with undetectable HBV DNA and persistently normal alanine aminotransferase

More information

Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup

Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup REVIEW REVIEW Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup Puneet Puri, M.B.B.S., M.D. and Arun J. Sanyal, M.B.B.S., M.D. Nonalcoholic fatty liver disease (NAFLD) is defined

More information

PATHOLOGY OF LIVER TUMORS

PATHOLOGY OF LIVER TUMORS PATHOLOGY OF LIVER TUMORS Pathobasic, 31.05.2016 WHO Classification Approach to a Liver Mass Lesion in a patient with chronic liver disease? Lesion in a patient without chronic liver disease? Malignant

More information

Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study

Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study ORIGINAL ARTICLE Annals of Gastroenterology (2017) 30, 357-363 Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study Spyridon A. Karageorgos

More information

Investigation of Ornithine Carbamoyltransferase as a Biomarker of Liver Cirrhosis

Investigation of Ornithine Carbamoyltransferase as a Biomarker of Liver Cirrhosis ORIGINAL ARTICLE Investigation of Ornithine Carbamoyltransferase as a Biomarker of Liver Cirrhosis Noriko Matsushita 1,2, Etsuko Hashimoto 1, Katsutoshi Tokushige 1, Kazuhisa Kodama 1, Maki Tobari 1, Tomomi

More information

HBV Therapy in Special Populations: Liver Cirrhosis

HBV Therapy in Special Populations: Liver Cirrhosis HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum

More information

A Simple Noninvasive Index Can Predict Hepatocellular Carcinoma in Patients with Chronic Hepatitis B

A Simple Noninvasive Index Can Predict Hepatocellular Carcinoma in Patients with Chronic Hepatitis B www.nature.com/scientificreports Received: 24 March 2017 Accepted: 25 July 2017 Published: xx xx xxxx OPEN A Simple Noninvasive Index Can Predict Hepatocellular Carcinoma in Patients with Chronic Hepatitis

More information

Transmission of HCV in the United States (CDC estimate)

Transmission of HCV in the United States (CDC estimate) Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong

More information

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France 41 year-old woman, coming to emergency department for fatigue

More information

Treatment of HCC in real life-chinese perspective

Treatment of HCC in real life-chinese perspective Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA

More information

Management of Chronic Hepatitis B in Asian Americans

Management of Chronic Hepatitis B in Asian Americans Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,

More information

In 1993, the International Autoimmune Hepatitis Group

In 1993, the International Autoimmune Hepatitis Group CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:417 421 Validation and Modification of Simplified Diagnostic Criteria for Autoimmune Hepatitis in Children ELIZABETH MILETI,* PHILIP ROSENTHAL,*, and MARION

More information

Chronic Cholestatic Liver Diseases

Chronic Cholestatic Liver Diseases Chronic Cholestatic Liver Diseases - EASL Clinical Practice Guidelines - Rome, 8 October 2010 Ulrich Beuers Department of Gastroenterology and Hepatology Tytgat Institute of Liver and Intestinal Research

More information

Chronic Hepatitis B: management update.

Chronic Hepatitis B: management update. Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)

More information

21/07/2017. Update on Autoimmune Biliary Disease. Changing Role of Liver Biopsy in PBC and PSC. Primary Biliary Cirrhosis Cholangitis

21/07/2017. Update on Autoimmune Biliary Disease. Changing Role of Liver Biopsy in PBC and PSC. Primary Biliary Cirrhosis Cholangitis Primary Biliary Cirrhosis Cholangitis Update on Autoimmune Biliary Disease Changing Change in Nomenclature for PBC : From Cirrhosis to Cholangitis (EASL Panel, Beuers et al J Hepatol Nov 2015, Gut Nov

More information

Liver Cancer. Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine

Liver Cancer. Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Liver Cancer Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Primary Liver Cancer Hepatocellular carcinoma (HCC) : > 80% Derived

More information

Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma

Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,

More information